Dose–response association of the ZJU index and fatty liver disease risk: A large cohort in China

2020 ◽  
Author(s):  
Xue Li ◽  
Pei Qin ◽  
Liming Cao ◽  
Yanmei Lou ◽  
Jing Shi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Dose Response ◽  
Fatty Liver Disease ◽  
Disease Risk ◽  
Large Cohort ◽  
Zju Index

scholarly journals Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 132
Author(s):  
Kenichiro Murayama ◽  
Michiaki Okada ◽  
Kenichi Tanaka ◽  
Chika Inadomi ◽  
Wataru Yoshioka ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Japanese Population ◽  
Fatty Liver Disease ◽  
Health Checkup ◽  
Nonalcoholic Fatty Liver ◽  
General Japanese Population ◽  
Advanced Liver Fibrosis ◽  
Zju Index

Access to imaging is limited for diagnosing nonalcoholic fatty liver disease (NAFLD) in general populations. This study evaluated the diagnostic performance of noninvasive and nonimaging indexes to predict NAFLD in the general Japanese population. Health checkup examinees without hepatitis virus infection or habitual alcohol drinking were included. Fatty liver was diagnosed by ultrasonography. The hepatic steatosis index (HSI), Zhejiang University (ZJU) index, and fatty liver index (FLI) were determined, and risk of advanced liver fibrosis was evaluated by the fibrosis-4 index. NAFLD was diagnosed in 1935 (28.0%) of the 6927 subjects. The area under the receiver operating characteristic (AUROC) curve of the HSI, ZJU index, and FLI was 0.874, 0.886, and 0.884, respectively. The AUROC of the ZJU index (p < 0.001) and FLI (p = 0.002) was significantly greater than that for the HSI. In subjects with a high risk of advanced fibrosis, the sensitivity of the HSI, ZJU index, and FLI were 88.8%, 94.4%, and 83.3% with a low cut-off value and the specificity was 98.5%, 100%, and 100% with a high cut-off value. In conclusion, all indexes were useful to diagnose NAFLD in the general Japanese population and in subjects with potentially advanced liver fibrosis.

A systematic review and a dose–response meta-analysis of coffee dose and nonalcoholic fatty liver disease

2019 ◽  
Vol 38 (6) ◽  
pp. 2552-2557 ◽  
Author(s):  
Yong-Ping Chen ◽  
Feng-Bin Lu ◽  
Yi-Bing Hu ◽  
Lan-Man Xu ◽  
Ming-Hua Zheng ◽  
...  
Keyword(s):  
Systematic Review ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Dose Response ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Nonalcoholic Fatty Liver

scholarly journals Association of fatty liver disease with mortality outcomes in an Eastern Finland male cohort

2019 ◽  
Vol 6 (1) ◽  
pp. e000219 ◽  
Author(s):  
Olubunmi O Olubamwo ◽  
Jyrki K Virtanen ◽  
Jussi Pihlajamäki ◽  
Tomi-Pekka Tuomainen
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Cancer Mortality ◽  
Fatty Liver Disease ◽  
Disease Risk ◽  
Study Cohort ◽  
Metabolic Factors ◽  
Disease Mortality ◽  
All Cause Mortality ◽  
Cvd Mortality

ObjectiveFatty liver disease (FLD) has been associated with extrahepatic morbidity outcomes. However, reports on the association of FLD, assessed using fatty liver index (FLI), with mortality outcomes have been inconsistent. Our objective was to examine the effect of metabolic factors (blood pressure, insulin, fasting glucose, lipoproteins) on the associations of FLI with mortality outcomes among middle-aged men.Study designProspective cohort study.MethodsOur subjects were 1893 men at baseline from 1984 to 1989 in the Kuopio Ischaemic Heart Disease Risk Factor Study cohort. Multivariable Cox regression models were used to analyse the association of baseline FLI, with the HRs for all-cause, disease, cardiovascular, non-cardiovascular and cancer mortality outcomes.ResultsThe mean FLI in the FLI categories were 16.2 in the low and reference category (FLI<30), 43.4 in the intermediate FLI category (FLI=30–<60) and 77.5 in the high FLI (FLD) category (FLI≥60). Over an average follow-up of 20 years, 848 disease deaths were recorded through Finnish national cause of death register. In models adjusted for constitutional, lifestyle and inflammatory factors, for the high (FLI≥60) vs low (FLI<30) FLI category, the HRs (95% CI) for mortality outcomes were 1.50 (1.26–1.78) for all-cause mortality; 1.56 (1.31–2.86) for disease mortality; 1.51 (1.18–1.94) for cardiovascular disease (CVD) mortality; 1.42 (1.12–1.80) for non-CVD mortality and 1.45 (1.02–2.07) for cancer mortality. With further adjustment for metabolic factors, the HRs were 1.25 (1.01–1.53) for all-cause mortality; 1.26 (1.02–1.56) for disease mortality; 1.06 (0.78–1.43) for CVD mortality; 1.46 (1.09–1.94) for non-CVD mortality and 1.49 (0.97–2.29) for cancer mortality.ConclusionHigh FLI (FLD) is associated with increased risks of mortality outcomes. The FLI-CVD mortality association can be largely explained by metabolic factors. Persons with FLD should be monitored for metabolic deterioration and extrahepatic morbidity to improve their prognoses.

Sign in / Sign up

Export Citation Format

Share Document